Syngene International Limited

Hurry! ⏰ If you are in and around #Copenhagen in September, join us at BioInnovation Institute for this exciting in-person event. Syngene is excited to host "Nordics Discovery", our inaugural scientific symposium, or as we like to call it, Syn-posium, in Europe, on preclinical research in the drug discovery space. The symposium will feature insights from our drug discovery experts Ralf Guenther and Miquel Salvà, who will discuss the latest advancements, strategies, and challenges in preclinical research. Whether you are a student, a postdoc, a faculty member, or a professional in the biotech or pharma sector, this symposium will offer you valuable insights and opportunities to advance your research. Don't miss this unique opportunity to join the focused preclinical research community. 👉 Register now! Note: This is an in-person event with limited seats. #NordicsDiscovery #DrugDiscovery #PreclinicalResearch #SyngeneSynposium #SyngeneDrugDiscovery

📌 Join Us at CPHI Milan 2024! We are excited to attend the CPHI Milan from October 8 - 10, 2024 in Fiera Milano, Italy. Meet us at Booth #7C114 to find out how Syngene can assist you in accelerating your non-GMP manufacturing programs. Book a meeting now (link in comments). Syngene is empowering global pharma innovators with leading-edge non-GMP manufacturing of regulatory starting materials (RSMs) with ISO certified cost-effective non-GMP manufacturing of Regulatory Starting Materials (RSMs) for both clinical and commercial Active Pharmaceutical Ingredients (APIs). As the demand for reliable, regulatory compliant suppliers grows, Syngene stands out as the best choice for non-GMP manufacturing in India. Our commitment to regulatory compliance, total quality management systems, cost effectiveness and technical excellence - makes us the preferred partner for your RSM needs. CPHI #CPHIMilan #DrugManufacturing #NonGMPManufacturing

📌PharmaBiz magazine has featured Syngene in an article titled “Pharma & Biotech Industry Propels ESG Implementation with Concerns Over Climate Change & Global Supply Disruptions”. Sibaji Biswas, Syngene's ED and CFO, shares insights on the evolving role of ESG in the pharmaceutical industry and how Syngene is leading the way in integrating green chemistry and renewable energy use into our operations, setting new benchmarks in environmental stewardship and ethical supply chain management. Read the full article 👉 https://lnkd.in/gE8cmHhK #Syngene #Sustainability

Are you looking for advanced preclinical research? Syngene offers a comprehensive suite of services, including validated pharmacodynamic and disease models, customized animal models, and preclinical toxicology expertise.   Our scientific and technical team specializes in a wide range of diseases, from inflammation and metabolic disorders to oncology/immuno-oncology, CNS disorders, pain, and cardiovascular and renal diseases.   Backed by our AAALAC-accredited and GLP-certified 67,000 sq. ft. animal laboratory, our models are rigorously supported with ex vivo assays, histopathology services, biomarkers, PK-PD studies, and imaging.   Explore our list of validated animal models 👉 https://lnkd.in/ghmXkyvr #drugdiscovery #preclinicalresearch

⏩ From Sequence to Vial in 10 Months: Accelerate Your mAb Development with Syngene's Comprehensive CDMO Services!   From cell line development to commercial manufacturing, Syngene offers a comprehensive solution for your monoclonal antibody projects. Our expertise includes: • Proprietary CHO line with >95% clonal stability • High-throughput process development • In-house analytical capabilities • Clinical manufacturing up to 2000L scale   🏆 Key Advantages: • 140+ successful projects • 25+ INDs enabled • 10 months from CLD to clinic • 7-12 g/L titers achieved   Ready to fast-track your mAb to market? Let's connect and explore how Syngene can accelerate your next breakthrough! Link in comments sections 🔗   #Syngene #CDMO #Biopharma #mAbDevelopment #DrugDiscovery

📌 Join Us at CPHI Milan 2024!   We are excited to attend the CPHI Milan from October 8 - 10, 2024 in Fiera Milano, Italy.   Meet us at Booth #7C114 to find out how Syngene can assist you in accelerating your R&D programs across Biologics.   We offer end-to-end integrated biologics solutions, covering Discovery, Development, and Commercial Manufacturing. Our advanced solutions can accelerate cell line development by 10 weeks and achieve high titers of up to 12g. We offer flexible scalability, with bioreactor capacities ranging from 50L to 2KL for clinical and commercial manufacturing, along with a sterile fill-finish capacity of 1 million vials per day, including both vials and pre-filled syringes (PFS).   Our facilities hold approvals from USFDA (with Zero 483 observations), EMA, and MHRA, along with certifications in GLP, GMP, and ISO standards.   We specialize in a wide spectrum of biologics, utilizing both mammalian and microbial expression systems. Our expertise includes monoclonal antibodies, bispecific antibodies, antibody fragments, recombinant proteins, glycoproteins, mRNA, and microbial systems like E. coli and Pichia. To book a meeting visit 👉 https://lnkd.in/gKPHYAwn #CPHIMilan #Biologics #CRDMO

📌Syngene was featured in C&EN's article, “India Seeks a Seat at the Drug Services Table.” The article explores the evolving landscape of contract development and manufacturing organizations (CDMOs) in India. Sibaji Biswas, Syngene's ED and CFO, shares insights on the growing preference of US pharmaceutical companies for India as a viable alternative to China amidst rising geopolitical tensions. Read the full article 👉 link in the comments section 🔗

📌 Get ready to dive into the future of protein production with Syngene's exciting webinar, 𝙎𝙮𝙣𝙒𝙚𝙖𝙫𝙚: 𝙄𝙣𝙩𝙚𝙜𝙧𝙖𝙩𝙞𝙣𝙜 𝙎𝙥𝙚𝙚𝙙, 𝙏𝙞𝙩𝙚𝙧, 𝙖𝙣𝙙 𝙌𝙪𝙖𝙡𝙞𝙩𝙮. Register now! #SynWeave #Syngene #Webinar #Biologics

📌 We are excited to attend ACS Fall 2024 event from August 18-22, 2024 at Denver, CO & Hybrid. Meet with our experts Anjan Chakrabarti and Nhakulan Dhamodharan to discuss how Syngene can help you accelerate your drug discovery programs. To book a meeting with our experts, visit the link in the comments section. 🔗 Our comprehensive suite of capabilities include - ⦿ Multiple Antibody Discovery Platforms: B cell cloning, hybridoma, display platforms, NGS, Tg mice, ADCs ⦿ Strong protein science and cell engineering team: Immunogens, engineered antibodies, structural biology, stable cell lines, gene editing tools ⦿ Complemented with expertise in assays, PK and in vivo efficacy models • Binding, function, IO and other assays, Bioassays for PK, and rodent disease models with PK-PD • Healthy and patient PBMC banking ⦿ Cell-line engineering: Characterization & validation, stability & cell banking and KI, KO cell lines ⦿ Integrated Discovery, Development & Manufacturing including cell line development, process development, DS and DP manufacturing, and sterile fill-finish. #ACSFall2024 #DrugDiscovery

We are pleased to announce that Pramuch Goel has joined Syngene as a member of our Executive Committee and ESG Council. He comes to Syngene from the Mahindra Group, where he served as Vice President and Head of Group Communications. In his role at Syngene, Pramuch will oversee Corporate Communications, Public Affairs, and ESG activities, leveraging his rich background to drive our strategic communications and sustainability initiatives. Read more: https://lnkd.in/gwE_eqHA